Navigation Links
Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
Date:10/21/2009

BETHESDA, M.D., Oct. 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months). Overall, 85% of the patients treated with DCVax®-Brain in the Company's prior trials have lived longer than the median survival of only 14.6 months which is achieved with the full standard of care treatment available today (i.e., surgery plus radiation and chemotherapy). Furthermore, 22% of the patients treated with DCVax®-Brain have now reached or exceeded the 6-year survival mark. With standard of care treatment, less than 5% of GBM patients are still alive at 5 years.

The median survival time of the patients treated with DCVax®-Brain in the prior trials is 36.4 months. The difference between this median survival and the median survival achieved with full standard of care treatment has a "p value" of 0.0004. This means that, as a matter of statistical significance, there is only a 4 in 10,000 chance that the DCVax® results are random.

In addition to showing such extended survival, patients treated with DCVax®-Brain in the prior clinical trials have shown striking delays in progression (recurrence) of their cancer. Typically, in spite of surgical removal of the initial tumor, as well as radiation and chemotherapy, GBM brain tumors recur in just 6.9 months. In contrast, in the patients treated with DCVax®-Brain in NWBT's clinical trials, so far 74% of the patients have been fre
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") announced ... its Telestroke and Teleneurology services. Dr. Ricardo Garcia-Rivera ... "We are extremely proud that our quality of service ... continue to provide lifesaving support and continuity of care ... throughout the United States ." ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... too, DENVER, Jan. 30 With the high ... want to heed advice,from two of the country,s leading ... speeches and pep rallies leading up to February 5, ... trail such as cheering,supporters, political pundits, and media analysts, ...
... Regional Healthcare System has,selected TransUnion,s Healthcare Revenue Cycle ... streamline administration of its charity,care policy., The ... hospital,system with campuses in Elyria, Amherst, and Avon, ... has served the needs of Lorain County and,greater ...
... 30 Sports and,nutritional product manufacturer, Natural Nutrition ... today a forward split of,its common stock. Each ... for every four shares owned as of the ... of record as of February 8, 2008, will ...
... stimulation (DBS) surgery, which is used to treat Parkinsons ... for its potential to treat a variety of conditions. ... to treat cluster headaches and aggressiveness in humans, and ... new study found that hypothalamic DBS performed in the ...
... Control No Matter Where,You Live, WASHINGTON, Jan. 30 ... the #1 Asthma Capital(TM) -- the most,challenging place to live ... Foundation of America (AAFA)., Since 2004, AAFA has conducted ... in America and to rank,them based on the quality of ...
... Jan. 29 John Josef Molenda has joined ... in the Firm,s Intellectual Property,and Appellate and Supreme ... an associate at Frommer Lawrence & Haug,LLP, where ... patent litigation. Dr. Molenda, who has a Ph.D. ...
Cached Medicine News:Health News:Candidates Risk Harming Voice in Final Week to Super Tuesday 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 3Health News:Natural Nutrition Announces Forward Split of Common Stock 2Health News:Deep brain stimulation may improve memory 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 3
The clarity and performance of glass with shatterproof safety of plastic....
Accurate and easy hematocrits in two minutes. Choose glass or easy to read SafeCrit plastic tubes, plain or heparinized. These tubes feature rapid capillary action and have a two-year shelf life. For...
... In the Innova™ 4100, the ... X-ray system for angiographic imaging, ... piece, non tiled Digital Detector ... reliably provide high resolution imaging ...
... is a bench-top fully automated random ... host of features usually only seen ... has the capacity to perform up ... ISEs, and offers primary tube sampling, ...
Medicine Products: